Colorectal Cancer | Specialty

Dr. Morse on Managing Toxicities and Sequencing Agents in mCRC

February 12th 2018

Michael A. Morse, MD, professor, Medicine, Department of Surgery, Duke University School of Medicine, Duke Cancer Institute, discusses factors that should be taken into consideration when sequencing agents in metastatic colorectal cancer.

Dr. Marshall on the Importance of Testing for BRAF Mutations in mCRC

February 12th 2018

John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, discusses the specificity now required in the treatment of patients with metastatic colorectal cancer (mCRC).

Dr. Jarnagin on the Improvements in Surgery for Patients With mCRC

February 12th 2018

William R. Jarnagin, MD, FACS, chief, Hepatopancreatobiliary Service, Benno C. Schmidt Chair, Surgical Oncology, Memorial Sloan Kettering Cancer Center, discusses the progression of surgery in treating patients with metastatic colorectal cancer.

Overman Highlights Latest Nivolumab Results in MSI-H/dMMR mCRC

February 8th 2018

Michael J. Overman, MD, discusses updated findings from the single-agent nivolumab CheckMate-142 cohort and combination data for nivolumab/ipilimumab from the pivotal trial.

Dr. Overman Discusses Immunotherapy and MSI Testing in CRC

February 8th 2018

Michael J. Overman, MD, associate professor, department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses immunotherapy and microsatellite instability (MSI) testing in colorectal caner (CRC).

Alpelisib Active in PIK3CA-Altered Solid Tumors

February 8th 2018

Alpelisib (BYL719) induced a disease control rate of 58.2% and stable disease rate of 52.2% in patients with advanced solid tumors.

CRC: Deciding on Duration of Adjuvant Therapy

February 8th 2018

Antibody Selection and Tumor Sidedness in CRC

February 8th 2018

Implications of Recent Data from CheckMate-142 in CRC

February 8th 2018

Early-Onset Colorectal Cancer: What Do We Know?

February 8th 2018

Dr. Bekaii-Saab Discusses the ReDOS Study in Metastatic CRC

February 6th 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the phase II regorafenib (Stivarga) dose optimization study (ReDOS) in metastatic colorectal cancer.

Dr. Jarnagin on Surgical Protocols for CRC That Have Spread Beyond the Liver

February 1st 2018

William R. Jarnagin, MD, FACS, chief, Hepatopancreatobiliary Service, Benno C. Schmidt Chair, Surgical Oncology, Memorial Sloan Kettering Cancer Center, discusses the surgical barriers in treating patients with colorectal cancer that has metastasized outside of the liver.

Dr. Andre on Nivolumab Plus Ipilimumab in dMMR/MSI-H mCRC

January 25th 2018

Thierry Andre, MD, professor of medical oncology, University Pierre et Marie Curie (UMPC), and Head of the Medical Oncology Department in St. Antoine Hospital, Assistance Publique Hôpitaux de Paris, discusses the results of the combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) in patients with DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer.

Nivolumab Alone or With Ipilimumab Provides Durable Benefit in MSI-H/dMMR mCRC

January 24th 2018

Data from the CheckMate-142 study support the use of nivolumab (Opdivo) alone or in combination with ipilimumab (Yervoy) for the treatment of patients with previously treated DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer.

Dr. Overman Discusses Nivolumab in Patients With dMMR/MSI-H mCRC

January 24th 2018

Michael J. Overman, MD, associate professor, department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses nivolumab (Opdivo) in patients with DNA mismatch repair-deficient/microsatellite instability-high metastatic CRC.

Older CRC Patients at Increased Risk for New-Onset Cardiotoxicity

January 23rd 2018

Older patients with colorectal cancer are more likely to develop cardiovascular disease and congestive heart failure, according to results from an analysis of the SEER database.

Napabucasin Plus Pembrolizumab Shows Early Promise in mCRC

January 23rd 2018

Combining the investigational oral cancer stem cell pathway inhibitor napabucasin with the PD-1 inhibitor pembrolizumab showed a signal of efficacy in the first 8 patients enrolled in a multicenter phase I/II trial of patients with metastatic colorectal cancer.

Dr. Bekaii-Saab Discusses QoL With Regorafenib Dose Escalation in mCRC

January 23rd 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the quality of life findings for a dose-escalation study of regorafenib (Stivarga) in metastatic colorectal cancer.

Cetuximab Plus Pembrolizumab Well Tolerated in RAS Wild-Type mCRC

January 21st 2018

The combination of cetuximab and pembrolizumab was found to be well tolerated in patients with RAS wild-type metastatic colorectal cancer.

Regorafenib Before Cetuximab Improves Survival in mCRC

January 21st 2018

Sequencing regorafenib before cetuximab showed superior overall survival compared with the reverse sequence in patients with metastatic colorectal cancer following failure of standard chemotherapy.